3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
3
Completed
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neuroblastoma
3
Lymphoma
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Unspecified Childhood Solid Tumor, Protocol Specific
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Sertoli-Leydig Cell Tumor
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian gynandroblastoma
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Leukemia
1
Immunoblastic Lymphadenopathy
1
Granulosa cell tumor of the ovary
1
Glioma
1
Fallopian Tube Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Carcinoma, Ovarian Epithelial
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
11
Rituximab
10
Gemcitabine
9
Paclitaxel
7
Lenalidomide
7
Decitabine
7
Cytarabine
7
Bendamustine Hydrochloride
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Carboplatin
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Antilymphocyte Serum
4
tislelizumab
3
pomalidomide
3
liposomal doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
etoposide phosphate
×
Clear all
NCT02015728
2016-12-15
SEED
Seattle Children's Hospital
Phase NA
Unknown
20 enrolled